Mirabegron
- Generic Name
- Mirabegron
- Brand Names
- Myrbetriq, Betmiga
- Drug Type
- Small Molecule
- Chemical Formula
- C21H24N4O2S
- CAS Number
- 223673-61-8
- Unique Ingredient Identifier
- MVR3JL3B2V
- Background
Mirabegron is a sympathomimetic beta-3 adrenergic receptor agonist used to relax the smooth muscle of the bladder in the treatment of urinary frequency and incontinence. It is unique amongst overactive bladder treatment options in that, unlike other treatments such as solifenacin and darifenacin, it lacks significant antimuscarinic activity, which is respons...
- Indication
Mirabegron is indicated for the treatment of overactive bladder (OAB) - with symptoms of urge urinary incontinence, urgency, and urinary frequency - either alone or in combination with solifenacin. It is also indicated for the treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35kg or more.
- Associated Conditions
- Neurogenic Detrusor Overactivity, Overactive Bladder Syndrome (OABS)
- Associated Therapies
- -
Mirabegron and Brown Adipose Tissue
- Conditions
- Interventions
- First Posted Date
- 2017-01-06
- Last Posted Date
- 2017-01-06
- Lead Sponsor
- Ingrid Jazet
- Target Recruit Count
- 20
- Registration Number
- NCT03012113
- Locations
- 🇳🇱
Leiden University Medical Center, Leiden, Zuid-Holland, Netherlands
Mirabegron for the Treatment of Pain Motivated Urinary Frequency and Urgency in Women
- Conditions
- Interventions
- First Posted Date
- 2016-12-05
- Last Posted Date
- 2020-10-22
- Lead Sponsor
- State University of New York at Buffalo
- Registration Number
- NCT02981459
- Locations
- 🇺🇸
UBMD Obstetrics and Gynecology, Buffalo, New York, United States
Brown Fat Activation Study
- Conditions
- Interventions
- First Posted Date
- 2016-09-29
- Last Posted Date
- 2020-02-07
- Lead Sponsor
- Philip Kern
- Target Recruit Count
- 39
- Registration Number
- NCT02919176
- Locations
- 🇺🇸
Center for Clinical and Translational Science, Lexington, Kentucky, United States
Mirabegron For Erectile Dysfunction
- Conditions
- Interventions
- First Posted Date
- 2016-09-27
- Last Posted Date
- 2021-01-05
- Lead Sponsor
- Johns Hopkins University
- Target Recruit Count
- 20
- Registration Number
- NCT02916693
- Locations
- 🇺🇸
Johns Hopkins Medical Institutions, Baltimore, Maryland, United States
The Effects of Normalizing Blood Pressure on Cerebral Blood Flow in Hypotensive Individuals With Spinal Cord Injury
- Conditions
- Interventions
- First Posted Date
- 2016-09-08
- Last Posted Date
- 2024-09-30
- Lead Sponsor
- James J. Peters Veterans Affairs Medical Center
- Target Recruit Count
- 21
- Registration Number
- NCT02893553
- Locations
- 🇺🇸
James J Peters VAMC, Bronx, New York, United States
🇺🇸Kessler Foundation Research Center, West Orange, New Jersey, United States
A Pilot Study of the Effects of Mirabegron on Symptoms in Patients With Interstitial Cystitis
- First Posted Date
- 2016-06-01
- Last Posted Date
- 2019-12-03
- Lead Sponsor
- Philadelphia Urosurgical Associates
- Target Recruit Count
- 9
- Registration Number
- NCT02787083
- Locations
- 🇺🇸
Philadelphia Urosurgical Associates, Philadelphia, Pennsylvania, United States
Beta3 Agonist Treatment in Chronic Pulmonary Hypertension Secondary to Heart Failure
- Conditions
- Interventions
- First Posted Date
- 2016-05-17
- Last Posted Date
- 2016-05-17
- Target Recruit Count
- 80
- Registration Number
- NCT02775539
A Study to Evaluate the Efficacy, Safety, and Tolerability of Mirabegron in Men With OAB Symptoms While Taking Tamsulosin Hydrochloride for Lower Urinary Tract Symptoms (LUTS) Due to Benign Prostatic Hyperplasia (BPH)
- Conditions
- Interventions
- First Posted Date
- 2016-05-02
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Global Development, Inc.
- Target Recruit Count
- 715
- Registration Number
- NCT02757768
- Locations
- 🇺🇸
Site US01009, Homewood, Alabama, United States
🇺🇸Site US01005, Huntsville, Alabama, United States
🇺🇸Site US01070, Hawaiian Gardens, California, United States
Open-label Phase 3 Study With Mirabegron in Children From 3 to Less Than 18 Years of Age With Neurogenic Detrusor Overactivity
- First Posted Date
- 2016-04-26
- Last Posted Date
- 2024-11-11
- Lead Sponsor
- Astellas Pharma Europe B.V.
- Target Recruit Count
- 91
- Registration Number
- NCT02751931
- Locations
- 🇷🇴
Site RO40001, Bucuresti, Romania
🇸🇰Site SK42101, Bratislava, Slovakia
🇯🇴Site JO96202, Amman, Jordan
Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain
- First Posted Date
- 2016-04-20
- Last Posted Date
- 2022-04-26
- Lead Sponsor
- Baylor College of Medicine
- Target Recruit Count
- 33
- Registration Number
- NCT02744430
- Locations
- 🇺🇸
Ben Taub General Hospital, Houston, Texas, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.